USA Financial Formulas’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$558 Hold
6
﹤0.01% 378
2025
Q4
$482 Buy
+6
New +$502 ﹤0.01% 383
2023
Q4
Sell
-1,146
Closed -$187K 337
2023
Q3
$187K Sell
1,146
-9
-0.8% -$1.58K 0.28% 96
2023
Q2
$212K Sell
1,155
-7
-0.6% -$1.01K 0.33% 52
2023
Q1
$155K Buy
+1,162
New +$137K 0.25% 53
2022
Q2
Sell
-1,485
Closed -$112K 322
2022
Q1
$112K Sell
1,485
-432
-23% -$29.5K 0.12% 82
2021
Q4
$143K Sell
1,917
-1,354
-41% -$80.2K 0.12% 91
2021
Q3
$154K Buy
3,271
+691
+27% +$30.1K 0.14% 125
2021
Q2
$104K Buy
+2,580
New +$107K 0.09% 165
2020
Q3
Sell
-14,274
Closed -$398K 316
2020
Q2
$398K Sell
14,274
-639
-4% -$15.6K 0.3% 52
2020
Q1
$273K Buy
+14,913
New +$347K 0.17% 93
2019
Q1
Sell
-10,690
Closed -$210K 120
2018
Q4
$210K Buy
+10,690
New +$190K 0.05% 256
2018
Q1
Sell
-12,685
Closed -$364K 307
2017
Q4
$364K Buy
+12,685
New +$399K 0.09% 201
2017
Q3
Sell
-48,760
Closed -$1.02M 242
2017
Q2
$1.02M Buy
+48,760
New +$1.03M 0.25% 92

Other funds holding ACLS

USA Financial Formulas's ACLS Position: Q1 2026 in Review

USA Financial Formulas held its Axcelis (ACLS) position steady in Q1 2026 at 6 shares worth $558. The position accounts for ﹤0.01% of the portfolio, ranked #378.

USA Financial Formulas first reported a position in ACLS in Q2 2017 and has held it in 14 quarters since. The position peaked at $1.02M in Q2 2017. 377 funds tracked by Wall St. Rank hold ACLS as of Q1 2026.

  • USA Financial Formulas held 6 shares of Axcelis worth $558 as of Q1 2026.
  • USA Financial Formulas left its Axcelis share count unchanged in Q1 2026.
  • Axcelis made up ﹤0.01% of USA Financial Formulas's portfolio in Q1 2026, its #378 holding.
  • USA Financial Formulas first reported a position in Axcelis in Q2 2017 and has held it in 14 quarters since.
  • USA Financial Formulas's Axcelis position peaked at $1.02M in Q2 2017.
  • 377 funds tracked by Wall St. Rank held Axcelis as of Q1 2026.

Based on USA Financial Formulas's 13F filing for Q1 2026, filed 14 Apr 2026.